Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system

다국어 초록 (Multilingual Abstract)

Multidrug resistance (MDR), the principalmechanism by which many cancers develop resistance tochemotherapy, is one of the major obstacles to the successfulclinical treatment of various types of cancer. Severalkey regulators are responsible for mediating MDR, aprocess that renders chemotherapeutic drugs ineffective inthe internal organelles of target cells. A nanoparticulatedrug delivery system (DDS) is a potentially promising toolfor circumventing such MDR, which can be achieved bytargeting tumor cells themselves or tumor endothelial cellsthat support the survival of MDR cancer cells. The presentarticle discusses key factors that are responsible for MDRin cancer cells, with a specific focus on the application ofDDS to overcome MDR via the use of chemotherapy ormacromolecules.

참고문헌 (Reference)

1 Boyle, P., "World Cancer Report 2008" Lyon:International Agency for Research on Cancer (IARC) 14-15, 2008

2 Kickhoefer, V. A., "Vaults are up-regulated in multidrug-resistant cancer cell lines" 273 : 8971-8974, 1998

3 Pastorino, F., "Vascular damage and anti-angiogenic effects of tumor vesseltargeted liposomal chemotherapy" 63 : 7400-7409, 2003

4 Maeda, H., "Tumor vascular permeability and the EPR effect in macromolecular therapeutics : A review" 65 : 271-284, 2000

5 Smith, K., "Topoisomerase IIa coamplification with erbB2 in human primary breast cancer and breast cancer cell lines-relationship to m-AMSA and mitoxantrone sensitivity" 8 : 933-938, 1993

6 Chabner, B. A., "Timeline : Chemotherapy and the war on cancer" 5 : 65-72, 2005

7 Danenberg, P. V., "Thymidylate synthetase : A target enzyme in cancer chemotherapy" 473 : 73-92, 1977

8 Lenz, H. J., "Thymidylate synthase mRNA level in adenocarcinoma of the stomach : A predictor for primary tumor response and overall survival" 14 : 176-182, 1995

9 Jonston, P. G., "Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumor" 55 : 1407-1412, 1995

10 Patil, Y. B., "The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance" 31 : 358-365, 2010

11 Siwak, D. R., "The potential of drug-carrying immunoliposomes as anticancer agents" 8 : 955-956, 2002

12 Zhang, B., "The expression and significance of MRP1, LRP, TOPOIIb, and BCL2 in tongue squamous cell carcinoma" 41 : 141-148, 2012

13 Kibria, G., "The effect of liposomal size on the targeted delivery of doxorubicin to Integrin avb3-expressing tumor endothelial cells" 34 : 5617-5627, 2013

14 Gao, S., "The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice" 17 : 1225-1233, 2009

15 Kanwar, J. R., "Targeting survivin in cancer : The cell-signalling perspective" 16 : 485-494, 2011

16 Wang, Z., "Targeting mirnas involved in cancer stem cell and EMT regulation : An emerging concept in overcoming drug resistance" 13 : 109-118, 2010

17 Chaudhary, A., "TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types" 21 : 212-226, 2012

18 Gupta, A.K., "Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications" 26 : 3995-4021, 2005

19 Rajagopal, A., "Subcellular localization and activity of multidrug resistance proteins" 14 : 3389-3399, 2003

20 Wang, R. B., "Structureactivity relationship : Analyses of p-glycoprotein substrates and inhibitors" 28 : 203-228, 2003

21 Zhou, S. F., "Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition" 38 : 802-832, 2008

22 Linton, K. J., "Structure and function of ABC transporters" 22 : 122-130, 2007

23 Ruoslahti, E., "Specialization of tumour vasculature" 2 : 83-90, 2002

24 Rejman, J., "Sizedependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis" 377 : 159-169, 2004

25 Takara, K., "Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy" 162 : 225-232, 2012

26 MacDiarmid, J. A., "Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug" 27 : 643-651, 2009

27 Jiang, J., "Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin" 76 : 170-178, 2010

28 Clapper, M. L., "Sensitization of human colon tumor xenografts to L-phenylalanine mustard using ethacrynic acid" 1 : 71-78, 1990

29 Soma, C. E., "Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles" 21 : 1-7, 2000

30 Wu, J., "Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil" 10 : 350-357, 2007

31 Hobbs, S. K., "Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment" 95 : 4607-4612, 1998

32 Shen, F., "Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance(MDR)in MDR human cancer cells" 324 : 95-102, 2008

33 Dziegiel, P., "Prognostic significance of metallothionein expression in correlation with Ki-67 expression in adenocarcinomas of large intestine" 18 : 401-407, 2003

34 Filipowicz, W., "Posttranscriptional gene silencing by siRNAs and miRNAs" 15 : 331-341, 2005

35 Patil, Y., "Polymeric nanoparticles for siRNA delivery and gene silencing" 367 : 195-203, 2009

36 Abu-Lila, A., "Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model" 134 : 18-25, 2009

37 List, A. F., "Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia" 87 : 2464-2469, 1996

38 Kunjachan, S., "Overcoming cellular multidrug resistance using classical nanomedicine formulations" 45 : 421-428, 2012

39 Hashizume, H., "Openings between defective endothelial cells explain tumor vessel leakiness" 156 : 1363-1380, 2000

40 Liu, C., "Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel" 140 : 277-283, 2009

41 Shintani, Y., "New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction" 104 : 790-795, 2003

42 Di Paolo, D., "Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK" 19 : 1131-1140, 2011

43 Zhang, L., "Nanoparticles in medicine : therapeutic applications and developments" 83 : 761-769, 2008

44 Haley, B., "Nanoparticles for drug delivery in cancer treatment" 26 : 57-64, 2008

45 Patil, Y., "Nanoparticlemediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance" 136 : 21-29, 2009

46 Bai, F., "Nanoparticlemediated drug delivery to tumor neovasculature to combat P-gp expressingmultidrug resistant cancer" 34 : 6163-6174, 2013

47 Murphy, E. A., "Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis" 105 : 9343-9348, 2008

48 Davis, M. E., "Nanoparticle therapeutics : An emerging treatment modality for cancer" 7 : 771-782, 2008

49 Peer, D., "Nanocarriers as an emerging platform for cancer therapy" 2 : 751-760, 2007

50 Hazlehurst, L. A., "Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line" 59 : 1021-1028, 1999

51 Gottesman, M. M., "Multidrug resistance in cancer : Role of ATP dependent transporters" 2 : 48-58, 2002

52 Kitazono, M., "Multidrug resistance and the lung resistancerelated protein in human colon carcinoma SW-620 cells" 91 : 1647-1653, 1999

53 Yuan, F., "Microvascular permeability and interstitial penetration of sterically stabilized(Stealth )liposomes in a human tumor xenografts" 54 : 3352-3356, 1994

54 Cherian, M. G., "Metallothioneins in human tumors and potential roles in carcinogenesis" 533 : 201-209, 2003

55 Kondo, Y., "Metallothionein null cells have increased sensitivity to anticancer drugs" 55 : 2021-2023, 1995

56 Shimoda, R., "Metallothionein is a potential negative regulator of apoptosis" 73 : 294-300, 2003

57 Chin, J. L., "Metallothionein in testicular germ cell tumors and drug resistance" 72 : 3029-3035, 1993

58 Kasahara, K., "Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin" 51 : 3237-3242, 1991

59 Dietel, M., "Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85–257" 50 : 6100-6161, 1990

60 Dalton, W. S., "Mechanisms of drug resistance in hematologic malignancies" 34 : 3-8, 1997

61 Luqmani, Y. A., "Mechanisms of drug resistance in cancer chemotherapy" 14 : 35-48, 2005

62 Toyoda, Y., "MRP class of human ATP binding cassette(ABC)transporters : Historical background and new research directions" 38 : 833-862, 2008

63 Raaijmakers, H. G., "Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma" 91 : 1029-1036, 1998

64 Scheffer, G. L., "Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer" 12 : 550-556, 2000

65 Walther, W., "Jet-injection of short hairpin RNA-encoding vectors into tumor cells" 629 : 123-139, 2010

66 Murakami, M., "Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting" 3 : 64ra2-, 2011

67 Laborde, E., "Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death" 17 : 1373-1380, 2010

68 Diestra, J. E., "Frequent expression of the multi-drug resistance associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material" 198 : 213-219, 2002

69 Meng, H., "Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line" 4 : 4539-4550, 2010

70 Izquierdo, M. A., "Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma" 87 : 1230-1237, 1995

71 Beck, W. T., "Drug resistance associated with altered DNA topoisomerase II" 33 : 113-127, 1993

72 Fischel, J. L., "Dihydropyrimidine dehydrogenase : Atumoral target for fluorouracil modulation" 1 : 991-996, 1995

73 Choi, H. S., "Design considerations for tumour-targeted nanoparticles" 5 : 42-47, 2010

74 Liu, L. F., "DNA topoisomerase poisons as antitumor drugs" 58 : 351-375, 1989

75 Wright, J. A., "DNA amplification is rare in normal human cells" 87 : 1791-1795, 1990

76 Rezzani, R., "Cyclosporine A and adverse effects on organs : Histochemical studies" 39 : 85-128, 2004

77 Sugahara, S., "Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate(AZ10992)" 117 : 40-50, 2007

78 Salonga, D., "Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase" 6 : 1322-1327, 2000

79 Wang, Y., "Codelivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer" 5 : 791-796, 2006

80 Saad, M., "Co-delivery of siRNA and an anticancer drug for treatment of multidrugresistant cancer" 3 : 761-776, 2008

81 Persidis, A., "Cancer multidrug resistance" 17 : 94-95, 1999

82 Huwyler, J., "By-passing of P-glycoprotein using immunoliposomes" 10 : 73-79, 2002

83 Sharma, A., "Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model" 53 : 5877-5881, 1993

84 Jain, R. K., "Antiangiogenic therapy for cancer : Current and emerging concepts" 19 : 7-16, 2005

85 Folkman, J., "Angiogenesis: An organizing principle for drug discovery?" 6 : 273-286, 2007

86 Bamias, A., "Angiogenesis in human cancer : Implications in cancer therapy" 14 : 459-469, 2003

87 Folkman, J., "Angiogenesis in cancer, vascular, rheumatoid and other disease" 1 : 27-31, 1995

88 Tewey, K. M., "Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II" 226 : 466-468, 1984

89 Choi, C. H., "ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal" 5 : 30-, 2005

90 Beck, A., "A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil" 30 : 1517-1522, 1994

91 Yamachika, T., "A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance" 82 : 70-77, 1998

92 Doyle, L. A., "A multidrug resistance transporter from human MCF-7 breast cancer cells" 95 : 15665-15670, 1998

93 Borst, P., "A family of drug transporters : The multidrug resistance-associated proteins" 92 : 1295-1302, 2000

94 Nakamura, K., "A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA" 19 : 2040-2047, 2011